Assistive Technology for Promoting the Independence and the Quality of Life in Persons With Alzheimer's Disease

2022 ◽  
pp. 173-195
Author(s):  
Donatella Ciarmoli
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Assistive Technology ◽  
Assistive Technologies ◽  
Memory Impairments ◽  
Physical Burden ◽  
Communication Difficulties ◽  
Challenging Behaviours

Persons with Alzheimer's disease (AD) may present a loss of cognitive functioning, memory impairments, communication difficulties, obstacles to perform daily activities, disorientation, and challenging behaviours. Currently, there is no cure for AD. However, there are valid treatments to alleviate AD-related symptoms and to reduce the burden on carers; for example, the effectiveness of the use of assistive technology (AT) has been seen. The aim was to provide, in this chapter, an overview of the newest empirical evidences available on the use of AT-based programs to improve the independence and the quality of life of patients with Alzheimer's disease and their caregivers. A selective literature review was carried out considering Alzheimer's, assistive technologies, dementia, quality of life, and caregivers. Empirical data demonstrated the effectiveness and the suitability of the AT interventions allowing participants to improve their quality of life, as well as to mitigate the mental and physical burden of their caregivers.

Validación de la escala Quality of Life in Alzheimer’s Disease (QOL-AD) en pacientes mexicanos con demencia tipo Alzheimer, vascular y mixta

2010 ◽  
Vol 51 (02) ◽  
pp. 72 ◽  
Author(s):  
Oscar Rosas Carrasco ◽  
Laura del Pilar Torres Arreola ◽  
María de Guadalupe Guerra Silla ◽  
Sara Torres Castro ◽  
Luis Miguel Gutiérrez Robledo
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease

Assessing Alzheimer's disease patients' quality of life: Discrepancies between patient and caregiver perspectives

2015 ◽  
Vol 12 (4) ◽  
pp. 427-437 ◽  
Author(s):  
Sandrine Andrieu ◽  
Nicola Coley ◽  
Yves Rolland ◽  
Christelle Cantet ◽  
Catherine Arnaud ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease

CLINICAL AND COST-EFFECTIVENESS OF DONEPEZIL, RIVASTIGMINE, AND GALANTAMINE FOR ALZHEIMER'S DISEASE

2002 ◽  
Vol 18 (3) ◽  
pp. 497-507 ◽  
Author(s):  
Andrew Clegg ◽  
Jackie Bryant ◽  
Tricia Nicholson ◽  
Linda McIntyre ◽  
Sofie De Broe ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cost Effectiveness ◽  
Global Health ◽  
Cochrane Library ◽  
The Impact ◽  
Health Cognition ◽  
Economic Studies

Objectives: Systematic review of the clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for people suffering from Alzheimer's disease.Methods: Sixteen electronic databases (including MEDLINE, the Cochrane Library, and Embase) and bibliographies of related papers were searched for published/unpublished English language studies, and experts and pharmaceutical companies were consulted for additional information. Randomized controlled trials (RCTs) and economic studies were selected. Clinical effectiveness was assessed on measurement scales assessing progression of Alzheimer's disease on the person's global health, cognition, functional ability, behavior and mood, and quality of life. Cost-effectiveness was presented as incremental cost per year spent in a nonsevere state (by Mini Mental Health State Examination) or quality-adjusted life-year.Results: Twelve of 15 RCTs included were judged to be of good quality. Although donepezil had beneficial effects in Alzheimer's patients on global health and cognition, rivastigmine on global health, and galantamine on global health, cognition, and functional scales, these improvements were small and may not be clinically significant. Measures of quality of life and behavior and mood were rarely assessed. Adverse effects were usually mild and transient. Cost-effectiveness base case estimates ranged from £2,415 savings to £49,476 additional cost (1997 prices) per unit of effect for donepezil and a small savings for rivastigmine. Estimates were not considered robust or generalizable.Conclusions: Donepezil, rivastigmine, and galantamine appear to have some clinical effect for people with Alzheimer's disease, although the extent to which these translate into real differences in everyday life remains unclear. Due to the nature of current economic studies, cost-effectiveness remains uncertain and the impact on different care sectors has been inadequately investigated. Further research is needed to establish the actual benefits of acetylcholinesterase inhibitors (AChEls) for people with Alzheimer's disease and their caregivers, the relationship of these changes to clinical management, and careful prospective evaluation of resource and budgetary consequences.

scholarly journals Quality of life of elderly with alzheimer’s disease: a comparative study between the patient’s and the caregiver’s report

2010 ◽  
Vol 18 (1) ◽  
pp. 26-32 ◽  
Author(s):  
Keika Inouye ◽  
Elisete Silva Pedrazzani ◽  
Sofia Cristina Iost Pavarini ◽  
Cristina Yoshie Toyoda
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Life Assessment ◽  
Quality Of Life Assessment ◽  
Patient Reports ◽  
The Family ◽  
Final Score ◽  
High Level

This paper aimed to compare the reports of patients and caregivers about how they perceive quality of life (QoL) in general and each of its dimensions in elderly with Alzheimer’s Disease (AD). The participants were elderly diagnosed with AD (n=53) attended by the Exceptional Medication Program in a city in the interior of Sao Paulo; and their respective family caregivers. The QoL measures were obtained through the Quality of Life Assessment Scale on Alzheimer’s Disease. The results showed statistically significant differences in the “memory” (p<0.05) and “you in general” (p<0.005) dimensions. Regarding the final score, the average in the patient’s version was 29.32 points (sd=6.27), against 28.33 points (sd=5.58) in the family version, p>0.100. Although the relative and patient reports were not identical, the results pointed to a high level of consistency among information.

Factors Associated with Caregivers’ Underestimation of Quality of Life in Patients with Alzheimer’s Disease

2012 ◽  
Vol 33 (1) ◽  
pp. 11-17 ◽  
Author(s):  
Hongmei Zhao ◽  
Jean-Luc Novella ◽  
Moustapha Dramé ◽  
Rachid Mahmoudi ◽  
Coralie Barbe ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Factors Associated

scholarly journals Factors related to perceived quality of life in patients with Alzheimer's disease: the patient's perception compared with that of caregivers

2009 ◽  
Vol 24 (6) ◽  
pp. 585-594 ◽  
Author(s):  
Josep Lluís Conde-Sala ◽  
Josep Garre-Olmo ◽  
Oriol Turró-Garriga ◽  
Secundino López-Pousa ◽  
Joan Vilalta-Franch
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Perceived Quality ◽  
Perceived Quality Of Life ◽  
Patient’S Perception
Sign in / Sign up

Export Citation Format

Share Document